TriLink BioTechnologies® and Aldevron sign agreement for CleanCap® mRNA Capping Technology

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company  and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines.

According to the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Aldevron’s mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology produces optimal 5’Cap structures with over 95% efficiency, creating a co-transcriptional capping solution that improves mRNA yield and process time when compared to legacy capping methods.

“CleanCap technology is accelerating programs through drug development milestones and has been the capping technology of choice for mRNA constructs in 350+ preclinical and clinical programs,” shared Becky Buzzeo, Chief Commercial Officer, Maravai. “We’re excited to offer our innovative capping solutions to Aldevron and its manufacturing customers.”

Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap® analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.

Aldevron, based in Fargo, ND, is a leader in advancing biological science. Their custom development and manufacturing services provide scientists with essential components to accelerate research and breakthrough discoveries.